KRAS and colorectal carcinoma: Thus, our studies demonstrated that SLC25A22 is an essential regulator of the metabolic system of KRAS-mutant colorectal tumor and its overexpression promotes tumor cell growth, which could provide more insights into KRAS-mutant CRC therapy with treatment of polyamine-inhibitor.